Immunotherapy harnesses the power of the immune system to treat cancer and other serious diseases. Our development of investigational treatments are stepping stones to tomorrow's breakthroughs.
Developing Two Novel Technologies
Juno is developing autologous cellular biologics as an answer to overcoming tumor evasion and potentially eradicating cancer cells. We believe the type of engineered T cell we put in the body matters, and we have developed the capability to manipulate and control the type of cells a patient receives, allowing us to develop potential “best-in-class” products that could deliver optimal therapeutic impact.
Chimeric Antigen Receptor (CAR) T cell Technology
Learn more about how our CAR T cells combine the specificity of an antibody with the cytotoxic properties of killer T cells.1-3
T Cell Receptor (TCR) Technology
Learn more about how our TCR constructs activate and co-stimulate T cells in a coordinated immune response against tumor cells.4
OVERCOMING TUMOR EVASION AND RESISTANCE
B cell malignancies—including ALL, CLL, and DLBCL—are some of the most intractable and difficult to treat. It is now widely understood that tumor cells’ ability to develop resistance and/or evade the immune response is likely a key driver of treatment failure.1, 5-9
In healthy individuals, normal T cells are able to identify antigens and effectively kill infected or abnormal cells, including cancer cells.10
Tumor cell variants adapt to selective pressure by the immune system and effectively evade the immune system’s surveillance by losing certain antigens, resulting in a lack of T cell recognition and ultimately resistance and/or recurrent disease.1
T Cell Inhibition
It has also been shown that tumor cells produce immunosuppressive cytokines, such as IL-10 and TGF-β1, in addition to expressing negative costimulatory molecules like PD-L1 that effectively inhibit T cell activity.1
HCPs looking for additional information on CAR T cell science and the latest advancements in cancer immunotherapy, please visit CARTCellScience.com.
Maus MV, Levine BL. Chimeric antigen receptor T cell therapy for the community oncologist. The Oncologist. 2016;21:1-10.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13:25-40.
Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492-500.
Chapius AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5:174ra27.
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541-1552.
Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817-4828.
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRS UKALL12/ECOG 2993 study. Blood. 2007;109:944-950.
Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2009;23:655-674.
Dighiero G, Hamblin TJ. Chronic lymphocytic leukemia. Lancet. 2008;371:1017-1029.
Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Philadelphia, PA: Saunders Elsevier; 2015.
ENGINEERED T CELL THERAPIES WILL CONTINUE TO EVOLVE
Juno is currently investigating two technologies – CARs (Chimeric Antigen Receptors) and TCRs (T cell Receptors) – to reprogram T cells from a patient’s own immune system to recognize and attack cancer cells.